Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Antibody-Drug conjugates

17 evidence topics · 17 sources

Antibody-drug conjugate positioning and sequencing: ABC8 consensus 2026

“In the ADC landscape, DESTINY-Breast06 showed that T-DXd can be an option for patients with HER2-low disease when the decision to initiate cytotoxic therapy is made, now earlier in the treatment sequence, as first-line cytotoxic therapy after progression on endocrine therapy and for whom further endocrine therapy was considered unsuitable, based on a 5.1-month improvement in median PFS over physician's choice chemotherapy (HR: 0.62), OS showed no statistically significant improvement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For patients with HER2 ultra-low disease, the available data remain limited and further evidence is required before a recommendation can be made.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In view of the modest PFS improvement, the absence of mature OS data, the side effect profile, and the availability of other treatment options, Dato-DXd in this setting is not a preferred option at present.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sacituzumab govitecan has moved to a less favored position in this subtype following the negative results of ASCENT-07, which failed to demonstrate superiority over single-agent chemotherapy as first-line cytotoxic therapy in ER+/HER2-negative ABC (median PFS by BICR: 8.3 months in both arms; HR: 0.85)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the absence of validated predictive biomarkers and robust evidence from prospective clinical trials, routine sequencing of ADCs in this setting cannot currently be recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote